Breaking News on Contract Research, Manufacturing & Clinical Trials

Top Headlines


Nobel prizes and the world’s top drug: a gallery of Scottish pharma

Scottish referendum: we look at Scotland's Nobel drug contributions

On the eve of the historical vote on Scottish independence from the UK tomorrow, we take a look at the pharma inventions Scotland gave the world.

News in brief

As contract manufacturers continue to consolidate , some in the industry are questioning whether the resulting companies have the ability to offer the same services as the former individual companies. 

The US FDA has warned the public not to use any sterile medicines made by Downing-owned NuVision Pharmacy, Texas, which failed to comply with a recall order.

Suppliers Albemarle, Siegfried USA and Johnson Matthey join CROs, CMOs and other leaders of the services sector in New Jersey, US this week to discuss all things outsourcing.

In a venture with plasma products manufacturer Octopharma, DHL has opened a €3.4m ($4.4m) cold-chain logistics centre in Germany for the pharma and life sciences industries.

Global Industry News


Moving EMA to DG Enterprise will increase risk of adverse events says NGO from

Shifting EMA oversight to DG Enterprise and Industry will put patients at greater risk of adverse events according to NGO Health Action International, which suspects EFPIA “had a hand” in planned European Commission reshuffle.

Indian drugmakers to bring cheap HCV drug Sovaldi to developing world from

Gilead has granted seven Indian drugmakers licenses to produce generic versions of its $1,000 a pill drug Sovaldi to increase access to hepatitis C medicines in 91 developing countries.

Galen plans to sell “green whistle” inhalable pain drug in UK and Ireland from

Almac’s subsidiary Galen has licensed UK sales and marketing rights to an emergency pain drug nicknamed the “green whistle” from Australian firm Medical Developments International (MVP).

Earn Billions: Learn how at’s Biosimilars forum from

Either the folks at Hospira, Celltrion, Samsung Biologics, Teva, Merck & Co and Quintiles are hopeless romantics investing in science for its own sake or, for them, the “debate” about the potential of biosimilars has already been resolved.   

'Fastest way to biosimilar approval? As the CRO flies,' says industry group from

Almost all of the biosimilars currently approved have been developed using a third-party research organisation according to a survey from the Association of Clinical Research Organizations (ACRO).

Merck KGaA is latest bi-curious antibody developer in ADC deal with Sutro from

Merck KGaA has partnered with bispecific antibody firm Sutro Biopharma to develop and produce antibody drug conjugates (ADCs).

Hospira bucks Australian generics downturn with $14m investment from

Hospira has invested 15m AUD ($14m) in a Victoria injectables plant it says will continue to make drugs for export despite the economic downturn and strong Australian dollar.


Evotec confirms orphan drug development status with Shire contract

Evotec teams with Shire on Fabry's disease as pharma interest in orphans grows

Evotec has partnered with Shire to develop inhibitors against Fabry’s disease and says such collaborations will grow...

CRL nears 85% capacity use, but says sector pricing won't improve yet

CRL nears 85% capacity use, but says sector pricing won't improve yet

Charles River Laboratories is approaching its optimal capacity utilisation but says pricing will not improve until the...

CMO issues persist as Cubist announces third recall for antibiotic

CMO issues persist as Cubist announces third recall for potential glass in antibiotic

For the third time since last August, Cubist Pharmaceuticals has recalled lots of its antibiotic Cubicin injection...

AMRI: Big Pharma still reliant on CMOs for sterile injectables

Injectables outsourcing growing despite pharma M&A, says AMRI

Big Pharma is still reliant on CMOs despite talk of returning in-house, says AMRI, which has launched...

Quintiles sees strong demand from large pharma

Quintiles sees strong demand from large pharma

Quintiles CEO Tom Pike told investors last week that the company is seeing “very strong demand from...

Almac announces Government backed recruitment drive

Almac announces Government backed recruitment drive

Northern Ireland-based contractor Almac will create 348 jobs over the next five years in its pharma and...

Key Industry Events


Access all events listing

Our events, Events from partners...